- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06585904
EFFECTS of BEETROOT JUICE INTAKE and PHYSICAL EXERCISE in POSTMENOPAUSAL HYPERTENSIVE WOMEN (EBJPEPHW)
EFFECTS of BEETROOT JUICE INTAKE and PHYSICAL EXERCISE in POSTMENOPAUSAL HYPERTENSIVE WOMEN: a RANDOMIZED, PLACEBO-CONTROLLED STUDY
The goal of this clinical trial is to verify the hemodynamic and biomarker responses of aerobic physical exercise and beetroot juice intake in postmenopausal women with hypertension. The main questions it seeks to answer are:
Is beetroot juice and aerobic exercise related to better hemodynamic responses in hypertensive postmenopausal women? Is beetroot juice and aerobic exercise related to better oxidative stress profile responses in hypertensive postmenopausal women?
The researchers will conduct a parallel clinical study with 10 days of intervention, in which 48 women will be randomized into 3 groups: 1) Aerobic exercise; 2) One shot of beetroot juice intake per day (400mg of NO3-); 3) Control (no intervention).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The entire intervention will take place at the Physical Education campus of University, in the Cardiorespiratory and Metabolic Physiology Laboratory (LAFICAM). The recruitment and approach of the volunteers will occur through media dissemination, such as radio announcements, television programs, and social media through digital media. After the dissemination, volunteers will make contact via phone, email, or social media, and a preliminary registration will take place. After this registration, the researchers will verify which volunteers meet the inclusion criteria, and only then will the recruitment take place.
The volunteers will be invited to come to LAFICAM to be informed about the intervention program and then sign the informed consent form. Before starting the intervention program, all volunteers must present a medical certificate clearing them to participate in a physical exercise training program; once the certificate is submitted, initial tests and general evaluations will be conducted.
The initial evaluations will consist of a questionnaire, anthropometric and body composition assessment, and evaluation of the physical activity level. After the questionnaires are administered, a familiarization with the sensory perceptions of beetroot juice will be conducted. This familiarization is important to verify if the volunteers are fit to carry out the intervention.
The volunteers will be randomized into three groups: Group 1: The volunteers will perform a moderate physical exercise session lasting 40 minutes for 10 consecutive days; Group 2: this group will ingest 70 ml of beetroot juice with 400 mg of nitrate every morning for 10 days. Group 3: this group will ingest 70 ml of beetroot juice without nitrate for 10 days.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
MG
-
Uberlândia, MG, Brazil, 38400-678
- FAEFI
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Amenorrhea for at least 12 months
- Controlled hypertension
- Suitable for physical exercise
- Present a certificate proving fitness to practice physical exercise
Exclusion Criteria:
- Decompensated hypertension in stages 2 and 3
- Having a history of stroke or acute myocardial infarction
- Smoker
- Having physical problems or cardiovascular complications that prevent physical exercise
- Having a diagnosis of Diabetes Mellitus
- Using hormone therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1 dose of beetroot juice
The volunteer will ingest 1 dose of beetroot juice containing 400mg of inorganic nitrate for 10 days.
|
The volunteer will ingest 1 dose of beetroot juice containing 400mg of inorganic nitrate for 10 days.
|
|
Active Comparator: Exercise
The volunteer will perform moderate aerobic exercise for 10 consultative days on a cycle ergometer.
|
The volunteer will perform moderate aerobic exercise for 10 consultative days on a cyclergometer.
|
|
No Intervention: Control
The volunteer will undergo initial assessments, will carry out the control without any intervention, for 10 consecutive days and will carry out the assessments afterwards.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemodynamic responses
Time Frame: 11 days
|
Volunteers will undergo blood pressure tests at the beginning, in the middle and after the 10 days of intervention.
To assess blood pressure (BP), researchers will use the Dyna Mapa + Cardius® device, programmed with measurements to be taken every 20 min.
Together with this device, the volunteers filled out a daily record of activities such as sleep, work, food, or any event that could interfere with BP or measurements.
In a standardized manner, the device was set at 7 a.m., and measurements were considered valid when 24h of monitoring were obtained.
Resting BP was measured with the same device after 15 min of rest in a sitting position, and for the analysis of the pressure curve, time 0 was adopted when the monitor was placed.
Sytolic BP, diastolic BP, and mean BP in periods of awake, sleep and 24 h were analyzed.
|
11 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stroop color and word test
Time Frame: 11 days
|
The evaluation of the blood pressure (BP) reactivity was carried out under mental stress, through the electronic version of Stroop protocol (3 minutes).
For the test, the volunteers sited in front of a computer screen with a headset and listened to a voice speaking names of different colors and with images changing every 2 seconds.
Each image consisted of a word forming the name of a color, with the word's letters color being different from the color's name, and with the bottom of the word with another color different from the color of the word and the color's name formed by the word.
The volunteers should speak as quickly as possible the name of the color formed by the letters in the image.
Before the test, baseline BP were measure once after resting in siting position during 15 minutes.
During the test, the volunteers BP was measured every minute, through the auscultatory method.
|
11 days
|
|
Superoxide Dismutase
Time Frame: 11 days
|
Superoxide Dismutase (SOD) activity will be assessed by inhibition of pyrogallol autoxidation.
Samples will be mixed with 50 mmol L Tris-HCl buffer (pH 8.2) containing 1 mmol L EDTA to deactivate metal-dependent enzymes, 80 U mL 1 catalase, and 24 mmol L 1 pyrogallol, and the kinetic assay will be monitored for 10 min at 420 nm using an analytical curve constructed with SOD as a standard.
|
11 days
|
|
Catalase
Time Frame: 11 days
|
Catalase (CAT) activity will be based on the decomposition of hydrogen peroxide.
Samples will be mixed with a 10 mmol_L^-1 potassium phosphate buffer (pH 7.0 containing 0.2% hydrogen peroxide.
Hydrogen peroxide decomposition will be monitored at 240 nm for 10 min.
|
11 days
|
|
Total antioxidant capacity due to ferric-reducing antioxidant power (FRAP)
Time Frame: 11 days
|
The total antioxidant capacity due to iron reducing antioxidant power (FRAP) will be determined by the ability of the antioxidants present in the blood samples to reduce Fe3+ to Fe2+, which is chelated by TPTZ (2,4,6-tris(2-pyridyl)-s-triazine) and forms the Fe2+ TPTZ complex.
This complex will be quantified in a spectrophotometer at 593 nm, and the antioxidant activity will be determined by means of an analytical curve, constructed with trolox as a standard.
|
11 days
|
|
Reduced glutathione (GSH)
Time Frame: 11 days
|
Plasma proteins will be precipitated with metaphosphoric acid (MPA) and centrifuged at 7000 g for 10 min.
The supernatant will be collected and mixed with 100 mM sodium phosphate buffer (pH 8.0) containing 5 mM EDTA and 15 μL ortho-phthaldialdehyde (1 mg/mL in methanol, HPLC grade, 99.9%).
The solution will be incubated in the dark at room temperature for 15 min.
Fluorescence will be read at 350 nm (excitation) and 420 nm (emission).
Glutathione (GSH) concentrations of the sample will be calculated using a GSH standard curve (0.001-0.1 mM)
|
11 days
|
|
Human cytokines
Time Frame: 11 days
|
Human cytokines (IL-8, IL-1β, IL-6, TNF, IL-10 and IL-12p70) in serum samples will be measured by flow cytometry technique (FACSCantoII BD™, San Jose, CA, USA) using a human inflammatory cytokine kit (BD™ Cytometric Bead Array (CBA), BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions.
|
11 days
|
|
Heart rate variability
Time Frame: 11 days
|
Resting R-R intervals will be recorded for 15 min in the seated position using an HR monitor (POLAR® RS800cx; Polar Electro Oy, Finland; sampling frequency = 1000 Hz) with spontaneous breathing.
Data will be down-loaded to a computer using an infrared interface with spe-cific software (POLAR PRO TRAINER5®, Polar Electro, Kempele, Finland).
Heart rate variability (HRV) analysis was performed using KUBIOS HRV 3.0.
Prior to the analysis, the signal will be visually inspected and filtered, and a range of 5 min interval with few artifacts will be selected near the end of the recording for analysis.
The resulting R-R intervals will be analyzed in the time domain, in the frequency domain using spectral analysis (Fast Fourier Transform) and non-linearly through the Poincaré diagram.
|
11 days
|
|
Glutationa peroxidase
Time Frame: 11 days
|
To measure glutathione peroxidase (GPx) activity, plasma will be incubated with GPx buffer (100 mM potassium phosphate containing 1 mM EDTA, pH 7.7), sodium azide (40 mM), glutathione (GSH) (diluted in 5% metaphosphoric acid), glutathione reductase (GR) (diluted in GPx buffer), NADPH (diluted with 5% sodium bicarbonate), and tert-butyl hydroperoxide (0.5 mM).
The reduction in NADPH concentration will be assessed for 10 min in a spectrophotometer at 340 nm.
|
11 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 02.78649524.4.0000.5152
- APQ-01874-18 (Other Grant/Funding Number: FAPEMIG)
- 175522/2023-5 (Other Grant/Funding Number: CNPq)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menopause
-
Western Norway University of Applied SciencesCompleted
-
Riphah International UniversityCompleted
-
Englewood Hospital and Medical CenterNanohealth, Inc.WithdrawnMenopause SymptomsUnited States
-
Englewood Hospital and Medical CenterNanohealth, Inc.CompletedMenopause SymptomsUnited States
-
University of Colorado, DenverCompletedMenopause | Pre-menopauseUnited States
-
S.LAB (SOLOWAYS)Center of New Medical TechnologiesCompletedMenopause SymptomsRussian Federation
-
Aydin Adnan Menderes UniversityUludag UniversityCompletedMenopause | Menopause Related ConditionsTurkey (Türkiye)
-
BHR Pharma, LLCTerminatedMenopause Related ConditionsGermany
-
Singapore General HospitalRecruitingMenopause | Menopause Related ConditionsSingapore
-
University of ArkansasCompletedMenopause Related ConditionsUnited States
Clinical Trials on 1 dose of Beetroot juice intake
-
Federal University of UberlandiaActive, not recruitingHypertension | MenopauseBrazil
-
Florida Institute for Human and Machine CognitionNot yet recruitingAging | Healthy Aging | Aging WellUnited States
-
University of British ColumbiaRecruitingInterstitial Lung DiseaseCanada
-
Poznan University of Physical EducationEnrolling by invitation
-
National Research Council, SpainIMDEA Food; CEIP (primary school) Jara Carrillo (Alcantarilla, Murcia, Spain); IES (secondary school) Alcántara (Alcantarilla, Murcia, Spain)CompletedGenotype, Metabotype and Dietary HabitsSpain
-
University of Sao PauloUniversity of Auckland, New ZealandCompleted
-
Jose Manuel Jurado CastroCompletedCaffeine | Placebo | Beetroot Juice | Beetroot Juice with Caffeine Co-ingestionSpain
-
International Medical UniversityTate & LyleCompleted
-
University of AlcalaCompletedNitrates | Caffeine | Resistance Exercise | Dietary Supplements | Sports PerformanceSpain
-
Heilongjiang Feihe Dairy Co. Ltd.Completed